Idetrexed

DB21469InvestigationalSmall molecule

Idetrexed is a small molecule drug. The usage of the INN stem '-trexed' in the name indicates that Idetrexed is a antineoplastic; thymidilate synthetase inhibitor. Idetrexed is under investigation in... Idetrexed is under investigation in clinical trial NCT02360345 (Phase I Trial of ONX-0801 Once Weekly or Alternate Weekly).

Mechanism: Pharmacologically active on Thymidylate synthase and Folate receptor alpha
Curator reviewed
Formula / weight: C₃₂H₃₃N₅O₁₀ · 647.641 g/mol (avg)
Code names: 6S-BGC-945 · BGC-945 · CB-300945 (S) · ONX-0801 · ONX-801

Resolves to

Compound

UNIIQ718FS1C7XCAS501332-69-0ChEMBLCHEMBL4594449ChEBI190251PubChem135487419

Structure

InChIKeyNVHRBQOZEMFKLD-CUYJMHBOSA-NSMILESOCC1=NC2=CC3=C(C=C2C(=O)N1)[C@H](CC3)N(CC#C)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(=O)N[C@H](CCC(O)=O)C(O)=O)C(O)=O

Targets

P04818TYMSP15328FOLR1P0A884thyA

What you can answer from here — as of September 23, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

13+ReferencesStructured and connected to the statements they support

Which drugs share a target with Idetrexed, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account